2-(E)-(3-甲氧基-4-环戊氧基苯基亚甲基)环戊酮衍生物的合成及抗肿瘤活性

2-(E)-(3-甲氧基-4-环戊氧基苯基亚甲基)环戊酮衍生物的合成及抗肿瘤活性

闫星, 马玉卓, 陈静波, 刘鹰翔^*

1. 广东药学院药科学院, 广东广州 510006;
2. 云南大学教育部自然资源药物化学重点实验室, 云南昆明 650091;
3. 广州中医药大学中药学院, 广东广州 510006

收稿日期:2007-06-02 修回日期:2007-11-10 出版日期:2007-12-15 发布日期:2007-12-15
通讯作者: 刘鹰翔*

Synthesis and antitumor activities of 2-(E)-(4-cyclopentyloxy-3-methoxylbenzylidene)cyclopentanone derivatives

Xing Yan, Yu-Zhuo Ma, Jing-Bo Chen, Ying-Xiang Liu^*

1. School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, China;
2. Key Laboratory of Medicinal Chemistry for Natural Resource (Yunnan University), Ministry of Education, School of Chemical Science and Technology, Kunming 650091, China;
3. School of Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou 510006, China

Received:2007-06-02 Revised:2007-11-10 Online:2007-12-15 Published:2007-12-15
Contact: Ying-Xiang Liu*

摘要/Abstract

摘要：

目的设计并合成一系列2-(E)-(3-甲氧基-4-环戊氧基苯基亚甲基)环戊酮衍生物, 并对其体外抗肿瘤活性进行筛选。方法合成目标化合物并用人肝癌细胞 (Bel-7402) 和人口腔癌细胞 (KB) 对化合物的体外抗肿瘤活性进行筛选。结果合成了5个目标化合物, 其中3个未见文献报道。化合物的结构经IR、1H NMR、MS和元素分析确证。初筛结果显示化合物5具有较高的活性, 对Bel-7402和KB细胞的IC50值分别为1.62 μmol·L–1和8.04 μmol·L–1, 但低于对照药5-氟脲嘧啶。结论 2-(E)-(3-甲氧基-4-环戊氧基苯基亚甲基) 环戊酮Mannich碱衍生物具有一定抗肿瘤活性。

关键词: 化学合成, 化学合成, 化学合成, 取代苯亚甲基环戊酮, 取代苯亚甲基环戊酮, 取代苯亚甲基环戊酮, 抗肿瘤活性, 抗肿瘤活性, 抗肿瘤活性

Abstract: Aim To design and synthesize a series of 2-(E)-(4-cyclopentyloxy-3-methoxylbenzylidene)cyclopentanone derivatives, and to determine their antitumor activities in vitro. Method The target compounds were synthesized. Their antitumor activities were assayed using human hepatic carcinoma cell line (Bel-7402) and human oral cavity epidermis squamocellular carcinoma cell line (KB). Results Five compounds were obtained. Three of them were not reported in the literature and their chemical structures were confirmed by IR, 1H NMR, MS and elemental analysis. Preliminary screening results showed that compound 5 possessed better biological activity with IC50 1.62 μmol·L–1 against Bel-7402 and 8.04 μmol·L–1 against KB, but much weaker than 5-Fluorouracil. Conclusion Mannich base derivatives of 2-(E)-(4-cyclopentyloxy-3-methoxylbenzylidene)cyclopentanone exhibited some antitumor activities.

Key words: Chemical synthesis, Chemical synthesis, Benzylidenecyclopentanone substituted, Benzylidenecyclopentanone substituted, Antitumor activity, Antitumor activity

中图分类号:

R916.2

Supporting: Foundation item: Natural Science Foundation of Guangdong Province (Grant No. 994615).
^*Corresponding author. Tel.: 86-20-39358251; 13826072145

闫星, 马玉卓, 陈静波, 刘鹰翔^*

. 2-(E)-(3-甲氧基-4-环戊氧基苯基亚甲基)环戊酮衍生物的合成及抗肿瘤活性[J]. .

Xing Yan, Yu-Zhuo Ma, Jing-Bo Chen, Ying-Xiang Liu^*. Synthesis and antitumor activities of 2-(E)-(4-cyclopentyloxy-3-methoxylbenzylidene)cyclopentanone derivatives[J]. .

参考文献

[1] Kupchan, S.M.; Eakin, M.A.; Thomus, A.M. J. Med. Chem. 1971, 14 (12): 1147–1152.
[2] Lee, K.H.; Meck, R.; Piantadosi, C.; Huang, E.S. J. Med. Chem. 1973, 16 (3): 299–301.
[3] Dimmock, J.R.; Kumar, P.; Nazarali, A.J.; Motaganahalli, N.L.; Kowalchuk, T.P.; Beazely, M.A.; Wilson Quail, J.; Oloo, E.O.; Allen, T.M.; Szydlowski, J.; DeClercq, E.; Balzarini, J. Eur. J. Med. Chem. 2000, 35(11): 967–977.
[4] Dimmock, J.R.; Raghavan, S.K.; Bigam, G.E. Eur. J. Med. Chem. 1988, 23 (2): 111–117.
[5] Dimmock, J.R.; Erciyas, E.; Bigam, G.E.; Kirkpatrick, D.L.; Duke, M.M. Eur. J. Med. Chem. 1989, 24 (4): 379–383.
[6] Zhou, S.L.; Ji, Z.Z. Chin. J. Med. Chem. 1990, 1(1): 26–33.
[7] Wang, J.L.; Zhao, L.X.; Wang, R.; Lu, M.; Chen, D.; Jing, Y.K. Bioorg. Med. Chem. 2005, 13(4): 1285–1291.
[8] Wang, W.; Liu, G.X.; Zheng, J. Eur. J. Pharmacol. 2007, 568(1): 61–67.
[9] Trachte, A.L.; Suthers, S.E.; Lerner, M.R.; Hanas, J.S.; Jupe, E.R.; Sienko, A.E.; Adesina, A.M.; Lightfoot, S.A.; Brackett, D.J.; Postier, R.G. Am. J. Surg. 2002, 184(6): 642–648.
[10] Adler, V.; Yin, Z.; Fuchs, S.Y.; Benezra, M.; Rosario, L.; Tew, K.D.; Pincus, M.R.; Sardana, M.; Henderson, C.J.; Wolf, C.R.; Davis, R.J.; Ronai, Z. EMBO J. 1999, 18(5): 1321–1334.
[11] Wang, T.; Arifoglu, P.; Ronai, Z.; Tew, K.D. J. Biol. Chem. 2001, 276(24): 20999–21003.
[12] Yin, Z.; Ivanov, V.N.; Habelhah, H.; Tew, K.D.; Ronai, Z. Cancer Res. 2000, 60(15): 4053–4057.
[13] Kamada, K.; Goto, S.; Okunaga, T.; Ihara, Y.; Tsuji, K.; Kawai, Y.; Uchida, K.; Osawa, T.; Matsuo, T.; Nagata, I.; Kondo, T. Free Radical Biol. Med. 2004, 37 (11): 1875–1884.
[14] Dimmock, J.R.; Smith, L.M. J. Pharm. Sci. 1980, 69 (5): 575–580.
[15] Ma, Y.Z.; Yin, L.N.; Liu, Y.X.; Mei, W.J.; Ji, Z.Z. Chin. J. Med. Chem. 2000, 16 (3): 144–149.